{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:48:21Z","timestamp":1793998101705,"version":"4.8.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1093\/toxsci\/kfx040","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T03:57:36Z","timestamp":1487131056000},"page":"374-384","source":"Crossref","is-referenced-by-count":77,"title":["Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury"],"prefix":"10.1093","volume":"163","author":[{"given":"Monicah A","family":"Otieno","sequence":"first","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Snoeys","sequence":"additional","affiliation":[{"name":"Preclinical Development & Safety, Janssen Pharmaceutica NV, Beerse, Antwerpen BE 2340, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Lam","sequence":"additional","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Player","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolism, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pocai","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolism, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Salter","sequence":"additional","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Simic","sequence":"additional","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Skaggs","sequence":"additional","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu","family":"Singh","sequence":"additional","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Keang","family":"Lim","sequence":"additional","affiliation":[{"name":"Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"key\n\t\t\t\t20180529090412_kfx040-B1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/hep.27206","article-title":"Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump","volume":"60","author":"Aleo","year":"2014","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2125.2012.04352.x","article-title":"Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling","volume":"75","author":"Bloomer","year":"2013","journal-title":"Br. J. Clin. Pharmacol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0041-008X(03)00368-5","article-title":"Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity","volume":"192","author":"Boelsterli","year":"2003","journal-title":"Toxicol. Appl. Pharmacol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/jgh.12516","article-title":"Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress","volume":"29","author":"Boelsterli","year":"2014","journal-title":"J. Gastroenterol. Hepatol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1021\/tx400183y","article-title":"Metabolism of xenobiotic carboxylic acids: Focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism","volume":"26","author":"Darnell","year":"2013","journal-title":"Chem. Res. Toxicol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B6","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.bmcl.2014.05.019","article-title":"Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus","volume":"24","author":"Defossa","year":"2014","journal-title":"Bioorgan. Med. Chem. Lett."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin. Pharmacol. Therap."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B10","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease","volume":"159","author":"Hofmann","year":"1999","journal-title":"Arch. Int. Med."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1152\/physrev.1989.69.3.708","article-title":"Functional specialization of different hepatocyte populations","volume":"69","author":"Jungermann","year":"1989","journal-title":"Physiol. Rev"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B12","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1517\/14656566.2013.851668","article-title":"Fasiglifam as a new potential treatment option for patients with type 2 diabetes","volume":"14","author":"Kaku","year":"2013","journal-title":"Expert Opin. Pharmacother"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/dom.12467","article-title":"Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: A randomized, double-blind, placebo-controlled, phase III trial","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes. Metab"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/dom.12693","article-title":"Long-term safety and efficacy of fasiglifam (TAK-875), a GPR40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: A 52-week open-label phase III study","volume":"18","author":"Kaku","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/dmd.113.054304","article-title":"Risk factors for development of cholestatic drug-induced liver injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4","volume":"42","author":"Kock","year":"2014","journal-title":"Drug Metab. Dispos"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B16","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1021\/acs.chemrestox.5b00315","article-title":"Toxicity of carboxylic acid-containing drugs: The role of acyl migration and CoA conjugation investigated","volume":"28","author":"Lassila","year":"2015","journal-title":"Chem. Res. Toxicol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/clpt.2012.43","article-title":"A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist TAK-875, in subjects with type 2 diabetes","volume":"92","author":"Leifke","year":"2012","journal-title":"Clin. Pharmacol. Therap."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/03602532.2011.605791","article-title":"Metabolic activation in drug-induced liver injury","volume":"44","author":"Leung","year":"2012","journal-title":"Drug Metab. Rev"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B19","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1021\/acs.chemrestox.5b00305","article-title":"The combination of anti-CTLA-4 and PD1-\/- mice unmasks the potential of isoniazid and nevirapine to cause liver injury","volume":"28","author":"Mak","year":"2015","journal-title":"Chem. Res. Toxicol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B20","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1021\/acs.chemrestox.5b00137","article-title":"The role of CD8 T cells in amodiaquine-induced liver injury in PD1-\/- mice cotreated with anti-CTLA-4","volume":"28","author":"Mak","year":"2015","journal-title":"Chem. Res. Toxicol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B21","author":"Marcinak","year":"2016"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B22","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.bcp.2004.08.003","article-title":"A gene expression signature for oxidant stress\/reactive metabolites in rat liver","volume":"68","author":"McMillian","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol. Sci."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0091270011409230","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers","volume":"52","author":"Naik","year":"2012","journal-title":"J. Clin. Pharmacol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/03602532.2011.604086","article-title":"Central role of mitochondria in drug-induced liver injury","volume":"44","author":"Pessayre","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2003.50331","article-title":"Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane","volume":"38","author":"Rius","year":"2003","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1124\/dmd.110.034173","article-title":"Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide","volume":"38","author":"Sawamura","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tiv.2015.09.019","article-title":"Minimizing DILI risk in drug discovery \u2013 A screening tool for drug candidates","volume":"30","author":"Schadt","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B31","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.bbamem.2013.05.007","article-title":"Progressive stages of mitochondrial destruction caused by cell toxic bile salts","volume":"1828","author":"Schulz","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfv152","article-title":"Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays","volume":"147","author":"Shah","year":"2015","journal-title":"Toxicol. Sci."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B34","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1194\/jlr.M062653","article-title":"Deoxycholic acid modulates cell death signaling through changes in mitochondrial membrane properties","volume":"56","author":"Sousa","year":"2015","journal-title":"J. Lipid Res."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B27","author":"Takeda Press Release","year":"2015"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B35","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1021\/tx300091x","article-title":"In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs","volume":"25","author":"Thompson","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B36","first-page":"202","article-title":"Mechanisms of drug-induced liver injury: From bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat. Rev."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: Past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425255.2015.981152","article-title":"New insights in the biology of ABC transporters ABCC2 and ABCC3: Impact on drug disposition","volume":"11","author":"van der Schoor","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2009.05.012","article-title":"New molecular insights into the mechanisms of cholestasis","volume":"51","author":"Wagner","year":"2009","journal-title":"J. Hepatol"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B40","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/nprot.2006.351","article-title":"Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes","volume":"1","author":"Will","year":"2006","journal-title":"Nat. Protoc"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B41","doi-asserted-by":"crossref","first-page":"240.","DOI":"10.3389\/fphar.2014.00240","article-title":"Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury","volume":"5","author":"Woodhead","year":"2014","journal-title":"Front. Pharmacol."},{"key":"key\n\t\t\t\t20180529090412_kfx040-B42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.2014.158","article-title":"Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity","volume":"96","author":"Yang","year":"2014","journal-title":"Clin. Pharmacol. Therap"},{"key":"key\n\t\t\t\t20180529090412_kfx040-B43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj20021081","article-title":"Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter","volume":"369","author":"Zelcer","year":"2003","journal-title":"Biochem. J."}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/toxsci\/article-pdf\/163\/2\/374\/24935035\/kfx040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T14:09:47Z","timestamp":1568815787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/163\/2\/374\/3001030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,16]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfx040","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2017,2,16]]}}}